- Home
- ELEV vs CMMB Comparison
ELEV vs CMMB Comparison
Compare ELEV & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- CMMB
- Stock Information
- Founded
- ELEV 2019
- CMMB 2004
- Country
- ELEV United States
- CMMB Israel
- Employees
- ELEV N/A
- CMMB N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- CMMB Health Care
- Exchange
- ELEV Nasdaq
- CMMB Nasdaq
- Market Cap
- ELEV 37.6M
- CMMB 23.6M
- IPO Year
- ELEV 2021
- CMMB N/A
- Fundamental
- Price
- ELEV $0.28
- CMMB $1.34
- Analyst Decision
- ELEV Buy
- CMMB Strong Buy
- Analyst Count
- ELEV 6
- CMMB 2
- Target Price
- ELEV $7.20
- CMMB $9.00
- AVG Volume (30 Days)
- ELEV 852.8K
- CMMB 141.4K
- Earning Date
- ELEV 03-06-2025
- CMMB 03-03-2025
- Dividend Yield
- ELEV N/A
- CMMB N/A
- EPS Growth
- ELEV N/A
- CMMB N/A
- EPS
- ELEV N/A
- CMMB N/A
- Revenue
- ELEV N/A
- CMMB N/A
- Revenue This Year
- ELEV N/A
- CMMB N/A
- Revenue Next Year
- ELEV N/A
- CMMB N/A
- P/E Ratio
- ELEV N/A
- CMMB N/A
- Revenue Growth
- ELEV N/A
- CMMB N/A
- 52 Week Low
- ELEV $0.42
- CMMB $0.58
- 52 Week High
- ELEV $5.83
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ELEV 22.43
- CMMB 38.69
- Support Level
- ELEV $0.46
- CMMB $1.21
- Resistance Level
- ELEV $0.55
- CMMB $1.53
- Average True Range (ATR)
- ELEV 0.05
- CMMB 0.15
- MACD
- ELEV -0.01
- CMMB 0.01
- Stochastic Oscillator
- ELEV 11.97
- CMMB 25.45
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.